Astragaloside IV Exerts a Myocardial Protective Effect against Cardiac Hypertrophy in Rats, Partially via Activating the Nrf2/HO-1 Signaling Pathway

Astragaloside IV protects against the pathological cardiac hypertrophy in mice

(2018) Zhen-hu Liu et al.   BIOMEDICINE & PHARMACOTHERAPY

Astragaloside IV inhibits ventricular remodeling and improves fatty acid utilization in rats with chronic heart failure

(2018) Bin Tang et al.   BIOSCIENCE REPORTS

Preventive effects of astragaloside IV and its active sapogenin cycloastragenol on cardiac fibrosis of mice by inhibiting the NLRP3 inflammasome

(2018) Yu Wan et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Canonical and non-canonical mechanisms of Nrf2 activation

(2018) Carlos Alfredo Silva-Islas et al.   PHARMACOLOGICAL RESEARCH

Astragaloside IV protects blood-brain barrier integrity from LPS-induced disruption via activating Nrf2 antioxidant signaling pathway in mice

(2018) Hongli Li et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Sulforaphane prevents angiotensin II-induced cardiomyopathy by activation of Nrf2 via stimulating the Akt/GSK-3ß/Fyn pathway

(2018) Ying Xin et al.   Redox Biology

Astragaloside IV Protects Rat Cardiomyocytes from Hypoxia-Induced Injury by Down-Regulation of miR-23a and miR-92a

(2018) Licheng Gong et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

Aspalathin Protects the Heart against Hyperglycemia-Induced Oxidative Damage by Up-Regulating Nrf2 Expression

(2017) Phiwayinkosi Dludla et al.   MOLECULES

Myricetin Possesses Potential Protective Effects on Diabetic Cardiomyopathy through Inhibiting IκBα/NFκB and Enhancing Nrf2/HO-1

(2017) Hai-han Liao et al.   Oxidative Medicine and Cellular Longevity

Airborne nitro-PAHs induce Nrf2/ARE defense system against oxidative stress and promote inflammatory process by activating PI3K/Akt pathway in A549 cells

(2017) Yu Shang et al.   TOXICOLOGY IN VITRO

Knockout of Eva1a leads to rapid development of heart failure by impairing autophagy

(2017) Shu Zhang et al.   Cell Death & Disease

Infl ammatory mediators in chronic heart failure in North India

(2017) Jan Fedacko et al.   ACTA CARDIOLOGICA

Research review on the pharmacological effects of astragaloside IV

(2016) Lei Li et al.   FUNDAMENTAL & CLINICAL PHARMACOLOGY

Physiological and pathological cardiac hypertrophy

(2016) Ippei Shimizu et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Plasma heme oxygenase-1 is decreased in peripheral artery disease patients

(2016) Salvatore Santo Signorelli et al.   Molecular Medicine Reports

Heart Disease and Stroke Statistics—2016 Update

(2015) Dariush Mozaffarian et al.   CIRCULATION

Cardiac Nonmyocytes in the Hub of Cardiac Hypertrophy

(2015) T. Kamo et al.   CIRCULATION RESEARCH

Astragaloside IV attenuates apoptosis of hypertrophic cardiomyocyte through inhibiting oxidative stress and calpain-1 activation

(2015) Meng Mei et al.   ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY

Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease

(2015) Lauren E. Tebay et al.   FREE RADICAL BIOLOGY AND MEDICINE

Molecular basis of the Keap1–Nrf2 system

(2015) Takafumi Suzuki et al.   FREE RADICAL BIOLOGY AND MEDICINE

Atrial natriuretic peptide in cardiovascular biology and disease (NPPA)

(2015) Wei Song et al.   GENE

Downregulation of Nuclear Factor Erythroid 2–Related Factor and Associated Antioxidant Genes Contributes to Redox-Sensitive Vascular Dysfunction in Hypertension

(2015) Rhéure A. Lopes et al.   HYPERTENSION

Nrf2 as an Endothelial Mechanosensitive Transcription Factor

(2015) Shane R. McSweeney et al.   HYPERTENSION

Nrf2 in ischemic neurons promotes retinal vascular regeneration through regulation of semaphorin 6A

(2015) Yanhong Wei et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Epidemiology of Heart Failure in Europe

(2015) Aldo Pietro Maggioni   Heart Failure Clinics

Effect of astragaloside IV against rat myocardial cell apoptosis induced by oxidative stress via mitochondrial ATP-sensitive potassium channels

(2015) FENG-YING GUAN et al.   Molecular Medicine Reports

Astragaloside IV Protects against Isoproterenol-Induced Cardiac Hypertrophy by Regulating NF-κB/PGC-1α Signaling Mediated Energy Biosynthesis

(2015) Suping Zhang et al.   PLoS One

Astragaloside IV Inhibits Doxorubicin-Induced Cardiomyocyte Apoptosis Mediated by Mitochondrial Apoptotic Pathway via Activating the PI3K/Akt Pathway

(2014) Yuanyuan Jia et al.   CHEMICAL & PHARMACEUTICAL BULLETIN

Angiogenesis and Cardiac Hypertrophy

(2014) Toru Oka et al.   CIRCULATION RESEARCH

Loss of NOX2 (gp91phox) prevents oxidative stress and progression to advanced heart failure

(2014) Nirmal Parajuli et al.   CLINICAL SCIENCE

Effects of Astragaloside IV combined with the active components of Panax notoginseng on oxidative stress injury and nuclear factor-erythroid 2-related factor 2/heme oxygenase-1 signaling pathway after cerebral ischemia-reperfusion in mice

(2014) Chang-Qing Deng et al.   Pharmacognosy Magazine

Diabetic cardiomyopathy: Mechanisms and new treatment strategies targeting antioxidant signaling pathways

(2014) Karina Huynh et al.   PHARMACOLOGY & THERAPEUTICS

The absence of macrophage Nrf2 promotes early atherogenesis

(2013) Anna-Kaisa Ruotsalainen et al.   CARDIOVASCULAR RESEARCH

Epidemiology of Heart Failure

(2013) Véronique L. Roger   CIRCULATION RESEARCH

NRF2 plays a protective role in diabetic retinopathy in mice

(2013) Zhenhua Xu et al.   DIABETOLOGIA

Regulation of Nrf2—an update

(2013) Suryakant K. Niture et al.   FREE RADICAL BIOLOGY AND MEDICINE

Endogenous Prostaglandin D 2 and Its Metabolites Protect the Heart Against Ischemia–Reperfusion Injury by Activating Nrf2

(2013) Yoshinori Katsumata et al.   HYPERTENSION

Astragaloside IV attenuates inflammatory cytokines by inhibiting TLR4/NF-кB signaling pathway in isoproterenol-induced myocardial hypertrophy

(2013) Juan Yang et al.   JOURNAL OF ETHNOPHARMACOLOGY

Prevention by sulforaphane of diabetic cardiomyopathy is associated with up-regulation of Nrf2 expression and transcription activation

(2013) Yang Bai et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Synergistic Promotion of Blood Vessel Regeneration by Astragaloside IV and Ferulic Acid from Electrospun Fibrous Mats

(2013) Huan Wang et al.   MOLECULAR PHARMACEUTICS

Astragaloside IV Protects against Cardiac Hypertrophy via Inhibiting the Ca2+/CaN Signaling Pathway

(2013) Meili Lu et al.   PLANTA MEDICA

Endothelial shear stress in the evolution of coronary atherosclerotic plaque and vascular remodelling: current understanding and remaining questions

(2012) J. J. Wentzel et al.   CARDIOVASCULAR RESEARCH

Biochemistry, Physiology, and Pathophysiology of NADPH Oxidases in the Cardiovascular System

(2012) Bernard Lassègue et al.   CIRCULATION RESEARCH

Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010

(2012) Theo Vos et al.   LANCET

Cardiac Response to Chronic Intermittent Hypoxia with a Transition from Adaptation to Maladaptation:The Role of Hydrogen Peroxide

(2012) Xia Yin et al.   Oxidative Medicine and Cellular Longevity

Triterpenoid Dihydro-CDDO-Trifluoroethyl Amide Protects against Maladaptive Cardiac Remodeling and Dysfunction in Mice: A Critical Role of Nrf2

(2012) Yifan Xing et al.   PLoS One

Up-regulation of p27kip1 contributes to Nrf2-mediated protection against angiotensin II-induced cardiac hypertrophy

(2011) Jinqing Li et al.   CARDIOVASCULAR RESEARCH

Discovery of the Negative Regulator of Nrf2, Keap1: A Historical Overview

(2010) Ken Itoh et al.   ANTIOXIDANTS & REDOX SIGNALING

An essential role of Nrf2 in American ginseng-mediated anti-oxidative actions in cardiomyocytes

(2010) Jinqing Li et al.   JOURNAL OF ETHNOPHARMACOLOGY